trending Market Intelligence /marketintelligence/en/news-insights/trending/Q1vL_06VMT2esKHwPWyWEA2 content esgSubNav
In This List

Novo Nordisk resubmits US FDA application for fast-acting insulin aspart

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Novo Nordisk resubmits US FDA application for fast-acting insulin aspart

Novo Nordisk A/S resubmitted to the U.S. FDA the new drug application for its fast-acting insulin aspart.

The treatment is intended to control postprandial glucose excursions in patients with type 1 and type 2 diabetes.

The FDA requested additional information from Novo Nordisk regarding the treatment in October 2016. The Denmark-based drugmaker has complied with the FDA's request and expects to receive feedback from the agency in the last quarter of 2017.

Fast-acting insulin aspart received marketing authorization from the European Commission on Jan. 9 and is under regulatory review in Switzerland, Australia, Brazil, South Africa, Argentina and Israel.